IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

NCT04003649 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Glioblastoma
Refractory Glioblastoma

Interventions

BIOLOGICAL: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration

Sponsor

City of Hope Medical Center

Collaborators

[object Object]
[object Object]
[object Object]